MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
0.7502
-0.0280
-3.60%
Closed 19:53 05/06 EDT
OPEN
0.7700
PREV CLOSE
0.7782
HIGH
0.7700
LOW
0.7106
VOLUME
176.37K
TURNOVER
0
52 WEEK HIGH
2.260
52 WEEK LOW
0.4500
MARKET CAP
56.53M
P/E (TTM)
-1.0389
1D
5D
1M
3M
1Y
5Y
1D
Cue Biopharma Inc <CUE.OQ> expected to post a loss of 15 cents a share - Earnings Preview
Reuters · 1d ago
Weekly Report: what happened at CUE last week (0428-0502)?
Weekly Report · 1d ago
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
NASDAQ · 4d ago
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
NASDAQ · 5d ago
Weekly Report: what happened at CUE last week (0421-0425)?
Weekly Report · 04/28 11:06
Weekly Report: what happened at CUE last week (0414-0418)?
Weekly Report · 04/21 11:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/15 21:05
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases
NASDAQ · 04/15 14:24
More
About CUE
More
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Recently
Symbol
Price
%Change
    CUE
  • 0.7502
  • -3.60%

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.